LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Assays to Measure Immunosuppressive Drugs Now Available

By LabMedica International staff writers
Posted on 27 Dec 2015
Print article
Two new clinical autoanalyzer tests for measurement of immunosuppressive drugs have been released to the market.

Roche (Basel, Switzerland) has announced the market availability of the new Elecsys Sirolimus and Everolimus immunosuppressive drug assays. These two assays complement the currently available Elecsys Tacrolimus and Cyclosporine assays, and with the mycophenolic acid (MPA) assay complete the Roche Diagnostics immunosuppressive drug monitoring portfolio.

The Elecsys family of assays offer performance based on Roche’s proven Elecsys heterogeneous immunoassay electrochemiluminescence (ECL) technology. The tests can be performed on any of the cobas modular platforms, including the cobas 4000 and cobas 6000 analyzer series, or the high-volume cobas 8000 modular analyzer series.

“Immunosuppressive drug monitoring requires a high level of precision to ensure that patients receive the optimal therapy. The new Elecsys ISD Assays will offer reliable, life-long testing to patients who have had organ transplants,” said Jean-Claude Gottraux, head of professional diagnostics at Roche. “This full offering also provides clinical laboratories with the opportunity to optimize their workflows and consolidate testing for a wide range of relevant markers on a single platform. This is a further example of the Roche commitment to invest in personalized healthcare”.

Related Links:

Roche 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more